- Previous Close
21.70 - Open
34.88 - Bid --
- Ask --
- Day's Range
34.00 - 79.02 - 52 Week Range
0.93 - 79.02 - Volume
24,281,968 - Avg. Volume
2,291,714 - Market Cap (intraday)
323.283M - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.64 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
brightmindsbio.com--
Full Time Employees
September 30
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: DRUG
View More
Performance Overview: DRUG
Trailing total returns as of 2024-10-18, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRUG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRUG
View MoreValuation Measures
Market Cap
97.16M
Enterprise Value
92.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
21.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.86%
Return on Equity (ttm)
-51.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.58M
Diluted EPS (ttm)
-0.64
Balance Sheet and Cash Flow
Total Cash (mrq)
6.19M
Total Debt/Equity (mrq)
0.23%
Levered Free Cash Flow (ttm)
-1.34M